ufmatic.blogg.se

Reduces the risk of fractures in patients with postmenopausalĬonditions and is therefore used to treat OP ( 4).

Zoledronic acid (ZA) is a potent antiresorptiveīisphosphonate that actively inhibits osteoclast proliferation, Of bisphosphonates that increase bone mass, strength and The bone degradation that occurs as a result of OP include the use The number of those experiencing hip fractures may rise to 6.26 That >200 million people have OP and it has been predicted that It is associated with a reduction inīone density, which increases bone fragility and the probability ofįracture, particularly of the hip, wrist and spine. Increased bone fragility and increasing the susceptibility ofĬommonly affects the elderly and its prevalence and associatedĬomplications are rapidly increasing worldwide ( 1). Osteoporosis (OP) is a bone disease characterized byĪ low bone mass and deterioration of bone tissue, leading to Most importantly, HZL in the lipid nanoparticle exhibited a strong affinity towards HA, further enhancing its efficacy in the treatment of OP. Furthermore, HZL NPs increased the cytotoxicity of HFOb 1.19 cells and increased the proportion of cells in the early (18.1☑2.4%), late (28.7☓.7%) and necrotic (67.5☑.2%) phases of apoptosis. There was sustained release behavior of the drug that maintained the drug reservoir effect at the bone site. In addition, a typical biphasic release pattern was observed that could be attributed to the presence of drug on the outer surface as well as on the inner core of the NPs.

Cellular morphology was investigated by scanning electron microscopy, which revealed clear spherical shaped NPs ~200 nm in size that could treat osteopores in the bone. Nanosized particles were prepared with the aim of increasing gradual and prolonged drug release and inducing toxicity of osteoblasts.

HA‑coated zoledronic acid loaded lipid bilayer nanoparticles (HZL NPs) were prepared using methods of extrusion and precipitation. The present study formulated a hydroxyapatite (HA)‑coated lipid nanoparticle loaded with zoledronic acid to treat patients with osteoporosis (OP).